Clinical Trial

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

Study acronym: KANDLELIT-014
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare * About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.
Protocol Amendment History 3 changes
notable Trial sites expanded: 66 -> 70 locations 2026-08-08
notable Trial sites expanded: 50 -> 55 locations 2026-05-12
notable Trial sites expanded: 46 -> 50 locations 2026-05-05
Trial Details
NCT Number NCT07209111
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Neoplasm Malignant
Enrollment 150 participants
Start Date 2025-12-04
Primary Completion 2032-04-09 (estimated)
Study Completion 2032-04-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-07